8 malignant pleural mesothelioma: a phase II study,” Clinical Lung Cancer, vol. 11, no. 1, pp. 30–35, 2010. [11] N. Androulakis, G. Aravantinos, K. Syrigos et al., “Oxali- platin as ﬁrst-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study,” Oncology, vol. 70, no. 4, pp. 280–284, 2006. [12] N. Ziras, A. Potamianou, I. Varthalitis et al., “Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-ﬂuorouracil plus irinotecan,” Oncology, vol. 70, no. 2, pp. 106–114, 2006. [13] N. Androulakis, K. Syrigos, A. Polyzos et al., “Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study,” Cancer Investigation, vol. 23, no. 1, pp. 9–12, 2005. [14] A. Polyzos, K. Syrigos, J. Stergiou et al., “Phase I trial of weekly docetaxel with a 4-weekly cisplatin administra- tion in patients with advanced gastric carcinoma,” Cancer Chemotherapy and Pharmacology, vol. 55, no. 5, pp. 466–470, 2005. [15] K. N. Syrigos, D. Karachalios, E. M. Karapanagiotou, C. M. Nutting, L. Manolopoulos, and K. J. Harrington, “Head and neck cancer in the elderly: an overview on the treatment modalities,” Cancer Treatment Reviews, vol. 35, no. 3, pp. 237–245, 2009. [16] D. Y. Yu, G. V. H. Dahl, R. S. Shames, and P. G. Fisher, “Weekly dosing of carboplatin increases risk of allergy in children,” Journal of Pediatric Hematology/Oncology, vol. 23, no. 6, pp. 349–352, 2001. [17] L. Lafay-Cousin, L. Sung, A.-S. Carret et al., “Carboplatin hypersensitivity reaction in pediatric patients with low- grade glioma: a canadian pediatric brain tumor consortium experience,” Cancer, vol. 112, no. 4, pp. 892–899, 2008. [18] M. Markman, A. Kennedy, K. Webster, B. Kulp, G. Peter- son, and J. Belinson, “Continued chemosensitivity to cis- platin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens,” Gynecologic Oncology, vol. 65, no. 3, pp. 434–436, 1997. [19] S. Kakolyris, N. Ziras, L. Vamvakas et al., “Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study,” Lung Cancer, vol. 54, no. 3, pp. 347–352, 2006. [20] R. F. Ozols, B. N. Bundy, B. E. Greer et al., “Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study,” Journal of Clinical Oncology, vol. 21, no. 17, pp. 3194–3200, 2003. [21] K. N. Syrigos, J. Vansteenkiste, P. Parikh et al., “Prognostic and predictive factors in a randomized phase III trial com- paring cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer,” Annals of Oncology, vol. 21, no. 3, pp. 556–561, 2010. [22] I. Gkiozos, A. Charpidou, and K. Syrigos, “Developments in the treatment of non-small cell lung cancer,” Anticancer Research, vol. 27, no. 4 C, pp. 2823–2827, 2007. [23] J. Souglakos, K. Syrigos, A. Potamianou et al., “Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as ﬁrst-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial,” Annals of Oncology, vol. 15, no. 8, pp. 1204–1209, 2004. Metal-Based Drugs [24] A. T. Dimou, K. N. Syrigos, and M. W. Saif, “Neuroendocrine tumors of the pancreas: what’s new,” Journal of the Pancreas, vol. 11, no. 2, pp. 135–138, 2010, highlights from the ”2010 ASCO Gastrointestinal Cancers Symposium”. [25] A. S. Strimpakos, K. N. Syrigos, and M. W. Saif, “Transla- tional research in pancreatic cancer,” Journal of the Pancreas, vol. 11, no. 2, pp. 124–127, 2010, highlights from the ”2010 ASCO Gastrointestinal Cancers Symposium”. [26] A. S. Strimpakos, K. N. Syrigos, and M. W. Saif, “Pharma- cogenetics in pancreatic cancer. Highlights from the ”45th ASCO Annual Meeting”. Orlando, FL, USA. May 29 - June 2, 2009,” Journal of the Pancreas, vol. 10, no. 4, pp. 357–360, 2009. [27] A. Strimpakos, M. W. Saif, and K. N. Syrigos, “Pancreatic cancer: from molecular pathogenesis to targeted therapy,” Cancer and Metastasis Reviews, vol. 27, no. 3, pp. 495–522, 2008. [28] K. N. Syrigos, D. Sitara, E. Georgiou, and K. J. Harrington, “Cytotoxic therapy of gastroenteropancreatic (GEP) tumors,” Anticancer Research, vol. 22, no. 2 B, pp. 1311–1314, 2002. [29] E. Syrigou, N. Makrilia, I. Koti, M. W. Saif, and K. N. Syrigos, “Hypersensitivity reactions to antineoplastic agents: an overview,” Anti-Cancer Drugs, vol. 20, no. 1, pp. 1–6, 2009. [30] K. M. Zanotti, L. A. Rybicki, A. W. Kennedy et al., “Car- boplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy,” Journal of Clinical Oncology, vol. 19, no. 12, pp. 3126–3129, 2001. [31] M. B. Callahan, J. A. Lachance, R. L. Stone, J. Kelsey, L. W. Rice, and A. A. Jazaeri, “Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer,” American Journal of Obstetrics and Gynecology, vol. 197, no. 2, pp. 199.e1–199.e5, 2007. [32] M. Markman, A. Kennedy, K. Webster et al., “Clinical features of hypersensitivity reactions to carboplatin,” Journal of Clinical Oncology, vol. 17, no. 4, pp. 1141–1145, 1999. [33] P. G. Rose, N. Fusco, M. Smrekar, K. Mossbruger, and M. Rodriguez, “Successful administration of carboplatin in patients with clinically documented carboplatin hypersen- sitivity,” Gynecologic Oncology, vol. 89, no. 3, pp. 429–433, 2003. [34] R. O’Cearbhaill, Q. Zhou, A. Iasonos et al., “The prophylactic conversion to an extended infusion schedule and use of pre- medication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment,” Gynecologic Oncology, vol. 116, no. 3, pp. 326–331, 2010. [35] P. A. Kosmidis, H. P. Kalofonos, C. Christodoulou et al., “Paclitaxel and gemcitabine versus carboplatin and gemc- itabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group,” Annals of Oncology, vol. 19, no. 1, pp. 115–122, 2008. [36] E. M. Karapanagiotou, A. Charpidou, I. Tzannou et al., “A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as ﬁrst-line therapy for non-small cell lung cancer,” Medical Oncology, vol. 25, no. 3, pp. 303–308, 2008. [37] V. Georgoulias, A. Ardavanis, A. Agelidou et al., “Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a ran- domized, multicenter phase III trial,” Journal of Clinical Oncology, vol. 22, no. 13, pp. 2602–2609, 2004.